ArticleEMBO reports2026
Pde1b controls cyclic nucleotide signaling in cDC1 and macrophages to regulate immune responses.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cyclic nucleotides cAMP and cGMP are potent suppressors of immune activation, yet how their intracellular levels are regulated within antigen-presenting myeloid cells remains undefined. Here we identify phosphodiesterase 1B (Pde1b) as a lineage-restricted regulator of cyclic nucleotide signaling in conventional type 1 dendritic cells (cDC1) and a subset of macrophages. Using genetic loss-of-function models and Listeria infection, we show that Pde1b is required for immune responses. Pde1b deficiency impairs bacterial clearance and reduces antigen-specific CD8+ and CD4 + T cell expansion, while myeloid transcriptional programs are skewed towards alternative and immunoregulatory states. These defects are largely attributable to DC dysfunction, as adoptive transfer of wild-type DC in Pde1b-deficient recipients partially rescues T cell priming. Macrophages exhibit parallel defects, including reduced frequency and impaired inflammatory and antimicrobial function. Mechanistically, Pde1b loss elevates cAMP and cGMP in cDC1 and macrophages, leading to increased PKA/PKG signaling and CREB-associated transcriptional reprogramming. Pharmacological inhibition of other phosphodiesterase families does not fully recapitulate Pde1b loss. Together, these findings identify Pde1b as a cell-type-specific regulator of cyclic nucleotide signaling essential for immune responses.
Identifiers
42744925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.